UNITED LAB Declines Initially Before Surging Nearly 9% to Exceed Threshold as 1H25 Net Profit Anticipated to Rise by 24%
Stock Performance: UNITED LAB (03933.HK) opened 6.5% lower at $15.2, reached a low of $15.02, but later rallied to close at $17.69, marking an all-time high of $17.81 during trading.
Trading Volume: The stock saw a trading volume of 34.8561 million shares, with a total value of approximately $579 million.
Profit Forecast: The company issued a positive profit alert, expecting a net profit of around RMB1.85 billion for the six months ending in June, which is a 24.1% increase from RMB1.491 billion in the same period of 2024.
Revenue Sources: The increase in net profit is largely attributed to approximately RMB1.1 billion from license fee income from Novo Nordisk A/S, despite declines in segment profits from Intermediate products and Bulk medicine.
Trade with 70% Backtested Accuracy
Analyst Views on 03933
No data
About the author
UNITED LAB Declines Initially Before Surging Nearly 9% to Exceed Threshold as 1H25 Net Profit Anticipated to Rise by 24%
Stock Performance: UNITED LAB (03933.HK) opened 6.5% lower at $15.2, reached a low of $15.02, but later rallied to close at $17.69, marking an all-time high of $17.81 during trading.
Trading Volume: The stock saw a trading volume of 34.8561 million shares, with a total value of approximately $579 million.
Profit Forecast: The company issued a positive profit alert, expecting a net profit of around RMB1.85 billion for the six months ending in June, which is a 24.1% increase from RMB1.491 billion in the same period of 2024.
Revenue Sources: The increase in net profit is largely attributed to approximately RMB1.1 billion from license fee income from Novo Nordisk A/S, despite declines in segment profits from Intermediate products and Bulk medicine.
UNITED LAB Declines Initially Before Surging Nearly 9% to Exceed Threshold as 1H25 Net Profit Anticipated to Rise by 24%
Stock Performance: UNITED LAB (03933.HK) opened 6.5% lower at $15.2, reached a low of $15.02, but later rallied to close at $17.69, marking an all-time high of $17.81 during trading.
Trading Volume: The stock saw a trading volume of 34.8561 million shares, with a total value of approximately $579 million.
Profit Forecast: The company issued a positive profit alert, expecting a net profit of around RMB1.85 billion for the six months ending in June, which is a 24.1% increase from RMB1.491 billion in the same period of 2024.
Revenue Sources: The increase in net profit is largely attributed to approximately RMB1.1 billion from license fee income from Novo Nordisk A/S, despite declines in segment profits from Intermediate products and Bulk medicine.
